{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:24:09Z","timestamp":1767839049173,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health research","doi-asserted-by":"crossref","award":["410006728"],"award-info":[{"award-number":["410006728"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Canadian Frailty Network","award":["CAT2017-08"],"award-info":[{"award-number":["CAT2017-08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The optimal treatment duration for patients with bloodstream infection is understudied. The Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) pilot randomized clinical trial (RCT) determined that it was feasible to enroll and randomize intensive care unit (ICU) patients with bloodstream infection to 7 versus 14\u2009days of treatment, and served as the vanguard for the ongoing BALANCE main RCT. We performed this BALANCE-Ward pilot RCT to examine the feasibility and impact of potentially extending the BALANCE main RCT to include patients hospitalized on non-ICU wards.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted an open pilot RCT among a subset of six sites participating in the ongoing BALANCE RCT, randomizing patients with positive non-<jats:italic>Staphylococcus aureus<\/jats:italic> blood cultures on non-ICU wards to 7 versus 14\u2009days of antibiotic treatment. The co-primary feasibility outcomes were recruitment rate and adherence to treatment duration protocol. We compared feasibility outcomes, patient\/pathogen characteristics, and overall outcomes among those enrolled in this BALANCE-Ward and prior BALANCE-ICU pilot RCTs. We estimated the sample size and non-inferiority margin impacts of expanding the BALANCE main RCT to include non-ICU patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 134 patients were recruited over 47 site-months (mean 2.9 patients\/site-month, median 1.0, range 0.1\u20134.4 patients\/site-month). The overall recruitment rate exceeded the BALANCE-ICU pilot RCT (mean 1.10 patients\/site-month, <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.0001). Overall protocol adherence also exceeded the adherence in the BALANCE-ICU pilot RCT (125\/134, 93% vs 89\/115, 77%, <jats:italic>p<\/jats:italic>\u00a0=\u20090.0003). BALANCE-Ward patients were older, with lower Sequential Organ Failure Assessment scores, and higher proportions of infections caused by <jats:italic>Escherichia coli<\/jats:italic> and genito-urinary sources of bloodstream infection. The BALANCE-Ward pilot RCT patients had an overall 90-day mortality rate of 17\/133 (12.8%), which was comparable to the 90-day mortality rate in the ICU pilot RCT (17\/115, 14.8%) (<jats:italic>p<\/jats:italic>\u00a0=\u20090.65). Simulation models indicated there would be minimal sample size and non-inferiority margin implications of expanding enrolment to increasing proportions of non-ICU versus ICU patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>It is feasible to enroll non-ICU patients in a trial of 7 versus 14\u2009days of antibiotics for bloodstream infection, and expanding the BALANCE RCT hospital-wide has the potential to improve the timeliness and generalizability of trial results.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Clinicaltrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02917551?id=NCT02917551+OR+NCT03005145&amp;rank=2&amp;load=cart\">NCT02917551<\/jats:ext-link>. Registered on September 28, 2016.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13063-019-4033-9","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T14:02:52Z","timestamp":1579096972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A pilot randomized controlled trial of 7 versus 14\u2009days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wards"],"prefix":"10.1186","volume":"21","author":[{"name":"on behalf of the Canadian Critical Care Trials Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Daneman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asgar H.","family":"Rishu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxandra","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaseen","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie P.","family":"Belley-Cote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Cirone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Downing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shay","family":"McGuinness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauralyn","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Muscedere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Parke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya","family":"Shehabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"4033_CR1","unstructured":"World Health Organization Antimicrobial Resistance. Global Report on Surveillance 2014: WHO; 2014. https:\/\/www.who.int\/drugresistance\/documents\/surveillancereport\/en\/."},{"issue":"11","key":"4033_CR2","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1128\/AAC.00627-10","volume":"54","author":"M Paul","year":"2010","unstructured":"Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54(11):4851\u201363.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4033_CR3","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","volume":"34","author":"A Kumar","year":"2006","unstructured":"Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589\u201396.","journal-title":"Crit Care Med"},{"issue":"10","key":"4033_CR4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","volume":"320","author":"PNA Harris","year":"2018","unstructured":"Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial. JAMA. 2018;320(10):984\u201394.","journal-title":"JAMA"},{"issue":"7","key":"4033_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/cid\/ciy1057","volume":"69","author":"Nick Daneman","year":"2018","unstructured":"Daneman N, Fowler RA. Shortening antibiotic treatment durations for bacteremia. Clin Infect Dis. 2019;69(7):1099\u2013100.","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"4033_CR6","doi-asserted-by":"publisher","first-page":"R267","DOI":"10.1186\/cc10545","volume":"15","author":"TC Havey","year":"2011","unstructured":"Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care. 2011;15(6):R267.","journal-title":"Crit Care"},{"key":"4033_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ijantimicag.2011.07.016","volume":"38","author":"N Daneman","year":"2011","unstructured":"Daneman N, Shore K, Pinto R, Fowler R. Antibiotic treatment duration for bloodstream infections in critically ill patients: A national survey of Canadian infectious diseases and critical care specialists. Int J Antimicrob Agents. 2011;38:480\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"4033_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/CCM.0000000000001393","volume":"44","author":"N Daneman","year":"2016","unstructured":"Daneman N, Rishu AH, Xiong W, et al. Duration of antimicrobial treatment for bacteremia in Canadian Critically ill patients. Crit Care Med. 2016;44(2):256\u201364.","journal-title":"Crit Care Med"},{"issue":"1","key":"4033_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13063-018-2474-1","volume":"19","author":"N Daneman","year":"2018","unstructured":"Daneman N, Rishu AH, Pinto R, et al. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: A pilot randomized clinical trial. Trials. 2018;19(1):111.","journal-title":"Trials"},{"issue":"1","key":"4033_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13063-015-0688-z","volume":"16","author":"N Daneman","year":"2015","unstructured":"Daneman N, Rishu AH, Xiong W, et al. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): study protocol for a pilot randomized controlled trial. Trials. 2015;16(1):173.","journal-title":"Trials"},{"issue":"1 Suppl","key":"4033_CR11","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1097\/CCM.0b013e3181920e33","volume":"37","author":"DM Arnold","year":"2009","unstructured":"Arnold DM, Burns KE, Adhikari NK, Kho ME, Meade MO, Cook DJ. The design and interpretation of pilot trials in clinical research in critical care. Crit Care Med. 2009;37(1 Suppl):S69\u201374.","journal-title":"Crit Care Med"},{"key":"4033_CR12","doi-asserted-by":"crossref","unstructured":"Yahav D, Franceschini E, Koppel F, et al. Seven versus fourteen days of antibiotic therapy for uncomplicated Gram-negative bacteremia: A non-inferiority randomized controlled trial. Clin Infect Dis. 2019;69(7):1091\u201398.","DOI":"10.1093\/cid\/ciy1054"},{"issue":"19","key":"4033_CR13","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","volume":"290","author":"J Chastre","year":"2003","unstructured":"Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588\u201398.","journal-title":"JAMA"},{"issue":"21","key":"4033_CR14","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1056\/NEJMoa1411162","volume":"372","author":"RG Sawyer","year":"2015","unstructured":"Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996\u20132005.","journal-title":"N Engl J Med"},{"issue":"5","key":"4033_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","volume":"380","author":"K Iversen","year":"2019","unstructured":"Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415\u201324.","journal-title":"N Engl J Med"},{"key":"4033_CR16","unstructured":"U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Hospital-Acquired Bacterial Pneumonia and Ventilator Asssociated Bacterial Pneumonia: Developing Drugs for Treatment. 5-5-2014. Ref Type: Online Source. https:\/\/www.fda.gov\/media\/79516\/download."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-4033-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-4033-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-4033-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:06:25Z","timestamp":1610582785000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-4033-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4033"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-4033-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"19 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was granted by the Clinical Trials Ontario, provincial REB. Informed consent was obtained from all study participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Rob Fowler is supported by a personnel award from the Heart and Stroke Foundation, Ontario Provincial Office. Dr. Deborah Cook holds a Canada Research Chair of Research Transfer in Intensive Care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}